Henry Schein, Inc. (NASDAQ:HSIC) Expected to Announce Quarterly Sales of $2.64 Billion

Wall Street analysts predict that Henry Schein, Inc. (NASDAQ:HSIC) will announce sales of $2.64 billion for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Henry Schein’s earnings. The lowest sales estimate is $2.61 billion and the highest is $2.67 billion. Henry Schein reported sales of $3.38 billion during the same quarter last year, which would suggest a negative year over year growth rate of 21.9%. The business is expected to announce its next earnings results on Wednesday, February 19th.

On average, analysts expect that Henry Schein will report full-year sales of $9.95 billion for the current fiscal year, with estimates ranging from $9.93 billion to $9.99 billion. For the next fiscal year, analysts forecast that the company will post sales of $10.30 billion, with estimates ranging from $10.26 billion to $10.38 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Henry Schein.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. Henry Schein had a return on equity of 15.93% and a net margin of 4.66%. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.52 billion. During the same period in the previous year, the business earned $1.03 EPS. The firm’s revenue was up 6.5% compared to the same quarter last year.

Several equities research analysts have issued reports on the company. Cleveland Research restated a “hold” rating on shares of Henry Schein in a research report on Friday, November 1st. UBS Group dropped their target price on Henry Schein from $57.00 to $56.00 and set a “sell” rating on the stock in a research report on Tuesday, November 12th. TheStreet upgraded Henry Schein from a “c+” rating to a “b” rating in a research report on Monday, October 14th. Zacks Investment Research downgraded Henry Schein from a “hold” rating to a “sell” rating and set a $71.00 target price on the stock. in a research report on Wednesday, November 6th. Finally, William Blair downgraded Henry Schein from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 7th. Six investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. Henry Schein currently has an average rating of “Hold” and a consensus target price of $70.75.

HSIC stock traded up $0.28 during trading on Thursday, reaching $68.46. 1,031,700 shares of the stock were exchanged, compared to its average volume of 1,084,338. The firm’s 50 day moving average is $63.90 and its 200 day moving average is $65.50. Henry Schein has a twelve month low of $56.58 and a twelve month high of $72.81. The firm has a market cap of $10.00 billion, a P/E ratio of 16.58, a price-to-earnings-growth ratio of 2.68 and a beta of 0.85. The company has a current ratio of 1.63, a quick ratio of 0.92 and a debt-to-equity ratio of 0.30.

Henry Schein announced that its board has initiated a stock repurchase program on Thursday, October 31st that authorizes the company to buyback $400.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 4.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

In related news, Director Paul Brons sold 1,758 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $69.34, for a total value of $121,899.72. Following the sale, the director now owns 15,824 shares in the company, valued at $1,097,236.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Steven Paladino sold 21,370 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $68.83, for a total value of $1,470,897.10. Following the completion of the sale, the chief financial officer now owns 144,863 shares in the company, valued at approximately $9,970,920.29. The disclosure for this sale can be found here. Insiders sold 123,655 shares of company stock worth $8,373,585 in the last quarter. 1.06% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of HSIC. Longview Partners Guernsey LTD raised its position in shares of Henry Schein by 15.8% in the second quarter. Longview Partners Guernsey LTD now owns 15,527,241 shares of the company’s stock worth $1,085,354,000 after buying an additional 2,117,869 shares in the last quarter. APG Asset Management N.V. raised its position in shares of Henry Schein by 1,735.2% in the second quarter. APG Asset Management N.V. now owns 822,308 shares of the company’s stock worth $50,474,000 after buying an additional 777,500 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Henry Schein by 142.5% in the second quarter. AQR Capital Management LLC now owns 927,381 shares of the company’s stock worth $64,648,000 after buying an additional 544,893 shares in the last quarter. Nuveen Asset Management LLC raised its position in shares of Henry Schein by 10,631.1% in the second quarter. Nuveen Asset Management LLC now owns 462,295 shares of the company’s stock worth $32,315,000 after buying an additional 457,987 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Henry Schein by 70.9% in the second quarter. Wells Fargo & Company MN now owns 1,064,399 shares of the company’s stock worth $74,401,000 after buying an additional 441,561 shares in the last quarter.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

See Also: How to build a Fibonacci channel

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.